Navigation Links
TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Date:5/14/2009

SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

The current clinical trial is being conducted at six centers in the USA. The study enrolled 28 patients in the dose-escalation phase (completed in February 2009) and 31 patients in the dose-confirmation phase of the study (currently in progress). Primary goals of this open-label study included identification of a maximum tolerated dose (MTD) in the dose-escalation phase and accumulation of safety data, assessments of drug effect on surrogate markers, biomarkers, and presumptive clinical endpoints in both phases of the study. Preliminary trial data presented at the 2008 ASH conference indicated that the drug was well tolerated and exhibited dose-dependant reductions of splenomegaly and leukocytosis. Updated clinical data pertaining to this trial are scheduled for presentation at the European Hematology Association (EHA) conference on June 6, 2009 in Berlin.

www.targegen.com

About TargeGen, Inc.

TargeGen, Inc. is a privately held biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors for applications in oncology and inflammatory diseases.


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
4. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
5. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Tris Pharma Announces Acceptance of Its First Two NDAs
8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
9. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
10. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
11. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... H1 2016"market research report that provides an overview ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/24/2016)... AMSTERDAM , May 24, 2016 ... aplicación médica para ayudar a los médicos a compartir ... los pacientes a escala mundial. Profesionales médicos de Europa, ... ya se han apuntado a la aplicación, que combina ... en un entorno totalmente seguro. Educación   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... ... a year and a half of planning the Multiple Pathways of Recovery Conference , ... Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel & ... explore the many pathways individuals use to get into and sustain their recovery. Pathways ...
(Date:5/27/2016)... ... 2016 , ... More than a third of American adults are considered obese, ... has received increased attention in recent years, as an article published May ... loss, most people are familiar with the basic requirements of maintaining a healthy diet ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross ... and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their ... Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ ...
(Date:5/27/2016)... ... 27, 2016 , ... An influential resource amongst nurses and professionals in the ... on the variety of topics detailing why we appreciate nurses in so many different ... has gone from being in a major recession to one of the hottest growing ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... factors of a stroke, which we as a society can control and change. , ... stroke occurs nearly every 40 seconds within the United States. Plus, with an estimated ...
Breaking Medicine News(10 mins):